Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection

Fig. 2

Comparison of survival outcomes for the DFS (A) and OS (B) in surgically treated stage III/N2 NSCLC patients after neoadjuvant therapy according to mGPS (Median DFS and OS were 7.3 vs. 29.17 months and 28.17 vs. 46.47 months, respectively; HR 0.595, 95% CI 0.335–1.056, p = 0.073; HR 0.587, 95% CI 0.331–1.042, p = 0.066). The values for the mGPS were defined as follows: mGPS 0, CRP ≤ 1 mg/dL and any albumin; mGPS 1, CRP > 1 mg/dL and albumin ≥ 35 g/L; mGPS 2, CRP > 1 mg/dL and albumin < 35

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us